Kornimate/medical-research-clean huggingface dataset:
effectiveness of enoxolone on oral conditions of patients with periodontal surgery

Conditions: Periodontal Surgery

Summary: abstract aim:the enoxolone (18β-glycyrrhetinic acid; bga) is a bioactive compound in licorice that exhibits potential anti-ulcer, anti-inflammatory, and anti-microbial activities, relieve oral ulcers, pain, improve gingivitis and dental plaque from past relevant experimental studies,but few clinical trials have evaluated its clinical effectiveness. therefore, the purpose of this study is to evaluate the effectiveness of enoxolone on oral conditions of patients with periodontal surgery. methods:this study is a randomized controlled trial. patients with severe chronic periodontitis who needed to accept periodontal surgery were randomly assigned to two groups, the experimental group was enoxolone toothpaste, and the control group for sensodyne toothpaste. after the operation, toothpaste was used three times a day to clean the mouth for 12 weeks . clinical evaluation was using the patient-reported pain score, painkillers, wound healing index (complete epithelization and color matching score), periodontal pocket depth, gingiva index, plaque index and were recorded before operation and 1st, 2nd, 3rd, 4th, 8th, 12th week after surgery. data set performs repeated-measures for the change in mean differences by using the two-tailed independent t tests and generalized linear model.

enoxolone is a toothpaste containing 18β-glycyrrhetinic acid (bga). in this study, the experimental group used enoxolone toothpaste, and the control group did not contain bga toothpaste (sensodyne), which is used for oral cleaning of patients after periodontal disease surgery. the absorption rate is very low, and it will not cause any interaction with western medicine.

Eligibility criteria:
inclusion criteria: * those who are over 20 years old. * those whose health or systemic diseases are well controlled. * those with severe chronic periodontitis who need to perform periodontal surgery after being diagnosed by a doctor. * subjects who are willing to accept this study. exclusion criteria: * allergy to licorice. * pregnancy or breastfeeding. * periodontal surgery completed at the same site within 6 months. * severe bone loss in the apical tissue of the surgical site (including poor prognosis). * clinical signs of infection, including fistula, suppuration, fever, severe pain and site swelling. * platelets less than 50,000.

Keywords: enoxolone wound healing plaque index.
website application based education and text messaging in improving skin wound care in patients undergoing mohs surgery

Conditions: Malignant Skin Neoplasm

Summary: this randomized clinical trial studies how well website application (web app) based education and text messaging works in improving skin wound care in patients undergoing mohs surgery (a surgical procedure used to treat skin cancer). website application and text messaging based education may help patients stick to wound care instructions before and after surgery, lower anxiety level, and may help monitor their activity.

primary objectives: i. to create a web application which will educate dermatologic surgery patients prior to their operations with educational videos. secondary objectives: i. to create and evaluate a web based system to send wound care instructions to patients by text message after their operation. ii. qualitative comments from participants and research staff concerning the feasibility of this approach and the use of fitbit activity trackers as a means to monitor movement restriction. iii. the rate of adverse events. outline: patients are randomized to 1 of 4 groups. group i: patients watch an educational video about mohs surgery before their surgery, a video about wound care after the surgery and receive text messages about wound care on days 1-5 after the surgery. patients also receive instructions to reduce movement and use a fitbit activity tracker. beginning 48 hours after surgery, patients are instructed to apply petroleum jelly twice daily (bid) to the wound area. group ii: patients watch an educational video about mohs surgery before their surgery, an educational video about wound care after the surgery and receive instructions to reduce movement and use a fitbit activity tracker. beginning 48 hours after surgery, patients apply petroleum jelly bid to the wound area. group iii: patients receive text messages about wound care on days 1-5 after the surgery and receive instructions to reduce movement and use a fitbit activity tracker. beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly bid to the wound are. group iv: patients receive no video or text messages. patients receive instructions to reduce movement and use a fitbit activity tracker. beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly bid to the wound area. after completion of study, patients are followed up at 1 week.

Eligibility criteria:
inclusion criteria: * the patient is undergoing mohs surgery * subject is capable of understanding and willing to provide a signed and dated written voluntary informed consent before any protocol specific procedures are performed * the subject is able to complete the study and comply with study instructions, including attending all study visits * the patient has a cell phone capable of receiving text messages exclusion criteria: * the patient is not indicated for mohs surgery * inability to complete all study-related visits * non-english speaking patients * the patient cannot receive text messages
the effect of erector spinae block on diaphragma movement

Conditions: Laparoscopic Cholecystectomy; Acute Post-operative Pain; Respiratory Diaphragm

Summary: laparoscopic cholecystectomy surgeries cause moderate/severe pain and thus can result in shallow breathing, atelectasis and increased opioid consumption in the early postoperative period which in turn cause a longer hospital stay. erector spinae plane block has been shown to decrease lower thoracic pain after laparoscopic cholecystectomy surgeries. this study aims to investigate the effect of erector spinae plane block on opioid consumption and diaphragma movement after laparoscopic cholecystectomy surgeries.


Eligibility criteria:
inclusion criteria: * ages between 18 and 65 * patients in american society of anesthesiologists classification i or ii * elective laparoscopic cholecystectomy surgery performed under general anesthesia exclusion criteria: * patient refusal * patients who can not provide informed consent or with a known psychiatric disease * patients with a known allergy to study drugs * patients using anticoagulants and corticosteroids * patients with diaphragma hernia, chronic obstructive pulmonary disease, lung cancer * patients who are not able to use a patient controlled analgesia device
genetic susceptibility to kidney cancer

Conditions: Renal Cell Carcinoma

Summary: this study will further the understanding of the genetic events leading to the development of rcc.

this study will further the understanding of the genetic events leading to the development of rcc; explore the genetic basis for genetic instability and how it affects cancer risk; and eventually provide a means of identifying a subgroup of individuals who are most likely to develop rcc. such individuals may then be targeted for intervention programs such as chemoprevention or dietary modification.

Eligibility criteria:
inclusion criteria: * adult patients of any ethnicity or sex, who have a been diagnosed with possible renal cell carcinoma within the past year. exclusion criteria: * must not have received chemotherapy, biological therapy or radiation therapy in the 6 months preceding enrollment will * must not have had rcc, or metastatic rcc, * must not have had a renal transplantation
bmx alpha registry: a post-market registry of the biomatrix alpha tm

Conditions: Coronary Artery Disease; Stable Angina; Ischemia; Acute Coronary Syndrome; NSTEMI; STEMI

Summary: prospective, multi-center, registry designed to enrol up to 2,000 patients in up to 35 international centers. all patients will receive a biomatrix alphatm stent as per clinical practice and will be followed for 2 years for data collection. major adverse cardiac events (mace) results at 9 months will be compared to the results obtained from the biomatrix flextm arm of the leaders trial.


Eligibility criteria:
inclusion criteria: * patients treated with the biomatrix alphatm stent per clinical indication and physician's choice; * patients who agree to comply with the follow up requirements; * patients with a life expectancy of \> 1 year at time of consent; * patients eligible to receive dual anti platelet therapy (dapt) according to guidelines; * hemodynamically stable patients. exclusion criteria: * inability to provide informed consent; * currently participating in another trial before reaching primary endpoint; * planned surgery within 6 months of percutaneous coronary intervention (pci) unless dual antiplatelet therapy is maintained throughout the perisurgical period; * patient has received an additional stent different from a biomatrix alphatm stent during the index procedure.
patients derived organoids as a promising tool to tailor ovarian cancer therapies (pandora).

Conditions: Ovarian Cancer

Summary: the association of clinical, pathogenesis and mutational profile of patients affected by ovarian cancer have improved the armamentarium of therapies available for medical doctors. one of most remarkable advancements is represented by the introduction of parp inhibitors in the front-line setting of advanced ovarian carcinoma. it is necessary to continue with this effort and introduce novel approaches to improve the survival rate as well as predictive biomarkers to approved therapies. given the absence of predictive biomarkers to standard therapy, patients derived organoid could be a promising platform to test clinically available drugs and/or promising new molecules to explore the tumor sensibility in an ex-vivo model. the aim of this study is to correlate treatment sensibility measured in tumor derived organoids to clinical sensibility seen in real world patients.

the association of clinical, pathogenesis and mutational profile of patients affected by ovarian cancer have improved the armamentarium of therapies available for medical doctors. one of most remarkable advancements is represented by the introduction of parp inhibitors in the front-line setting of advanced ovarian carcinoma. it is necessary to continue with this effort and introduce novel approaches to improve the survival rate as well as predictive biomarkers to approved therapies. given the absence of predictive biomarkers to standard therapy, patients derived organoid could be a promising platform to test clinically available drugs and/or promising new molecules to explore the tumor sensibility in an ex-vivo model. the aim of this study is to correlate treatment sensibility measured in tumor derived organoids to clinical sensibility seen in real world patients.

Eligibility criteria:
inclusion criteria: 1. signed informed consent form; 2. female sex; 3. age ≥18 years; 4. diagnosis of ovarian cancer; 5. availability of tumor sample or ascites that is planned to be stored in the institutional biobank for research purpose exclusion criteria: 1. patients for which the tumor/ascites biobanking process could compromise the diagnostic assessments; 2. pregnancy or breast-feeding 3. history of concomitant or previous malignancy in the last 5 years
a study to evaluate the effect of sarpogrelate on blood hyperviscosity

Conditions: Peripheral Artery Disease, PAD

Summary: this study is to evaluate the effect of sarpogrelate on blood viscosity after 24 weeks in patients with high blood viscosity.


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with pad\* (\*criteria for diagnosis of pad: diagnosed with burger's disease, obstructive arteriosclerosis, diabetic peripheral vascular disease, or with ischemic symptoms such as ulcers, pain, cold sensation, etc.) 2. todi \< 3 at randomization 3. aged ≥ 19 years 4. written informed consent exclusion criteria: 1. patients requiring acute or two or more antiplatelet agents 2. patients requiring anticoagulant therapy 3. patients requiring surgical procedure due to vascular occlusion 4. patients whose results are confirmed at the screening as follows: * hemoglobin (hb) test value: male \< 13 g/dl, female \< 12 g/dl * platelet count \< 60,000/µl * severe renal disease (egfr \< 30 ml/min/1.73 m2) 5. patients with a history of cerebrovascular and cardiovascular complications (cerebral infarction, transient ischemic attack, myocardial infarction, unstable angina, coronary artery bypass, percutaneous coronary intervention) within the last 6 months 6. contraindications stated in the spc of sarpogrelate 7. patients who are pregnant or planning to become pregnant 8. those participating in other clinical trials with administration of investigational products at the screening 9. those who are deemed to be ineligible to participate in the trial by investigator
evaluation of macular edema after acf implant's injection, 1 month after the last dxm implant

Conditions: Macular Edema

Summary: patients with diabetic macular edema (dme) or uveitis-related macular edema who have failed first-line therapy such as anti-vegf, laser treatments, or dexamethasone implants (dxm) are candidates for treatment with an intravitreal injection of a fluocinolone acetonide (acf) implant. acf is unique in that it delivers intravitreal corticosteroids for 2 to 3 years, whereas dxm only releases them for 3 to 6 months. after 6 months for acf and 1 month for dxm, full therapeutic efficacy is attained. acf's safety and efficacy have now been confirmed in the fame originator studies as well as other phase iv investigations. however, in the fame princeps trials and numerous phase iv trials where patients got acf more than 6 months after dxm, up to 40% of patients required laser, anti-vegf, and/or dxm retreatment within the acf active period. this high rate could be attributed to acf's 6-month delay in reaching full efficacy. this is why the investigators intended to replicate the previous iluvi1-month research, which shown that injecting dxm at 1 month preserved visual acuity and central retinal thickness for the first 6 months without increasing intraocular pressure significantly. the study, however, was unable to determine the long-term impact on the rate of relapses requiring additional therapy as well as tolerance with the development of long-term cortisone-induced glaucoma. in light of this, the investigators should like to gather new data for a 3-year follow-up after acf injection, including measurements of optic nerve fibre thickness (oct rnfl). this is an essential safety data point because it assesses the long-term effects of ocular hypertension, which is a well-known side effect of intravitreal corticosteroids.


Eligibility criteria:
inclusion criteria: * patient (male, female)°≥ 18 years old * having received an acf injection 1 month after a dxm injection * for diabetic macular edema or uveitic macular edema exclusion criteria: * patient's refusal to allow his or her medical data to be used for research purposes
dni values after periodontal treatment

Conditions: Periodontitis; Periodontal Inflammation; Inflammatory Response

Summary: the study included 70 systemically healthy individuals, as a test group of 35 patients with stage 3, grade a periodontitis and a control group of 35 individuals with no periodontal disease. blood samples were taken for the examination of dni, white blood cells (wbc), immature granulocytes (ig), procalcitonin, c-reactive protein (crp), lymphocyte count and neutrophil count. for the patients with periodontitis, blood sample assays were repeated 3 months after nspt.

the role of the delta neutrophil index (dni) in the pathogenesis and follow-up of periodontal disease has not been comprehensively documented. the study included 70 systemically healthy individuals, as a test group of 35 patients with stage 3, grade a periodontitis and a control group of 35 individuals with no periodontal disease. blood samples were taken for the examination of dni, white blood cells (wbc), immature granulocytes (ig), procalcitonin, c-reactive protein (crp), lymphocyte count and neutrophil count. for the patients with periodontitis, blood sample assays were repeated 3 months after nspt.

Eligibility criteria:
inclusion criteria: * patients diagnosed with periodontitis * patients have more than 20 teeth in the mouth * minimum age 18 * maximum age 65 exclusion criteria: * patients with any systemic disease * active smokers * pregnant or breastfeeding * patients have used any antibiotic or anti-inflammatory drug in the last 6 months * patients have received any periodontal treatment in the last 6 months.
real-world evaluation of glp-1 receptor agonists (glp-1ra) on efficacy and persistence, adherence and therapeutic inertia among type 2 diabetes adults with obesity

Conditions: Type 2 Diabetes; Obesity

Summary: type 2 diabetes (t2d) is a progressive chronic condition associated with a high morbi-mortality that has a considerable impact on healthcare resources. glucagon-like peptide-1 receptor agonists (glp-1ra) are incretin mimetics that have been shown to improve glycemic control with a low associated risk of hypoglycemia. additionally, previous studies have linked the use of glp-1ra with a reduction in the risk of cardiovascular events and kidney disease progression. despite these positive results, glp1-ra´s prescription, following the failure of treatment with metformin monotherapy or dual therapy, remains low in spain compared to other countries in our milieu. furthermore, the use of this therapeutic class is not homogeneous across the different autonomous communities in spain, and, no objective justification for these differences seems to exist. consequently, there is a need to understand which are the benefits associated with the use of glp-1ra, versus intensification with other oral agents, in real-life conditions. in this study, the impact of the use of glp-1ra on clinical outcomes such as all-cause mortality, cardiovascular and renal outcomes as well as severe hypoglycemia will be evaluated based on the analysis of longitudinal databases that collect the variables of interest generated in a real-life scenario. in addition, both persistence and adherence to treatment in patients treated with glp-1ra and its impact on the clinical outcomes of interest will be studied. finally, therapeutic inertia will be analyzed. all these data will contribute to generating cost-effective strategies aimed at improving health outcomes among t2d patients in our setting, reinforcing persistence and adherence to the prescribed treatment, and reducing therapeutic inertia in this group of patients. since the use of glp-1ra versus intensification with other oral agents has been associated with better glycemic control, and, when compared to intensification with basal insulin, with a lower incidence of severe hypoglycemia, we hypothesized that t2d adults treated with glp-1ra would present a lower incidence of cardiovascular and renal outcomes and fewer hospitalizations due to severe hypoglycemia events as well as a decreased all-cause mortality. on the other hand, patients on glp-1ra who would present greater persistence and adherence to treatment should experience fewer cardiovascular and renal outcomes and lower mortality compared to those with less persistence and adherence. finally, it is possible that the type of glp-1ra and the mode of administration, weekly versus daily, may influence adherence, persistence and therapeutic inertia in this group of patients.


Eligibility criteria:
inclusion criteria: * adults with type 2 diabetes * individuals with at least a 6-month prescription exclusion criteria: * individuals below 18 * individuals with less than a 6-month prescription
patient characteristics and treatment patterns from early crizanlizumab use in real-world setting: preliminary analysis from select sickle cell centers

Conditions: Sickle Cell Disease

Summary: this was a retrospective cohort study using secondary data from member sites of the national alliance of sickle cell centers (nascc) with at least five patients who initiated crizanlizumab. patients who were prescribed crizanlizumab were included in the cohort.


Eligibility criteria:
inclusion criteria: * any patient with diagnosis of scd based on high-performance liquid chromatography (hplc) or hemoglobin electrophoresis at treating institution * treatment order for crizanlizumab; index date was defined as the date for the first crizanlizumab treatment * at least 12 months of available electronic medical record (emr) data pre-index date (baseline) * patients must have received at least one dose of crizanlizumab * for inclusion in pre/post analysis of effectiveness, patients must have received at least 6 doses of medication. the rates could be annualized if total post-index time was \<12 months. exclusion criteria: none specified
safety and efficacy study of raav2-nd4 treatment of leber hereditary optic neuropathy (lhon)

Conditions: Leber Hereditary Optic Neuropathy

Summary: this study is meant to assess the safety and efficacy of raav2-nd4 treatment of leber hereditary optic neuropathy with 11778 lhon mutation.

leber's hereditary optic neuropathy (lhon) is a maternally inherited ocular disorder associated with a mutation in mtdna . the common manifestation is visual loss which caused by the respiratory chain enzymes complex dysfunction resulting in increased oxidative stress enzymes production. material and method seven patients with 11778 lhon mutation were randomly treated with a single ivt injection of recombinant adeno-associated virus-nadh dehydrogenase, subunit 4 (complex i)（raav2-nd4)（0.05ml).the dose was 5 × 10\^9 vg/0.05 ml for patients younger than 12 years old, and 1 × 10\^10 vg/0.05 ml for patients older than 12 years old. the visual acuity, visual evoked potential （vep）,optical coherence tomography（ oct）, computerized visual field, electroretinograms(erg), retinal nerve fiber layer(rnfl)and liver and kidney function in plasma were compared before and after treatment at 1,3,and 6, months interval.

Eligibility criteria:
inclusion criteria: 1. comply with leber hereditary optic neuropathy diagnostic criteria. 2. in patients with informed consent, voluntary participation. 3. signed informed consent. 4. 8 ≤ age ≤ 60 years old, good health, the patient can tolerate local anesthesia surgery. 5. to comply with doctor's instructions, can in the time of referral. exclusion criteria: 1. cardiopulmonary and renal function in severe weakness, cancer, a variety of bleeding disorders, acute sensing disease, high fever, high fever disease, women during pregnancy, heart disease, such as post-operative recovery period. 2. are participating in other clinical studies of patients. 3. patients with mental disorders.

Keywords: leber's hereditary optic neuropathy,11778 lhon mutation, raav2-nd4,triamcinolone acetonide